Maine is a drug tracked in our intelligence system with 5 linked articles.
Maine regulators selected an 800 MW wind farm and a 1.2 GW transmission line from bids, signaling progress on utility-scale wind.
Seven Democratic-led states sued the Interior Department to block a March deal that would reimburse TotalEnergies roughly $795 million for bailing on offshore wind leases, arguing the arrangement unlawfully uses taxpayer funds and threatens wind-energy deployment.
NECEC’s early operation shows limited net new hydropower to New England, with outages and Phase 2 dynamics dampening promised gains and leaving long-run benefits conditional on weather and regulatory terms.
Heat pumps are nearing parity with, and may soon outsell, conventional ACs in the US, supported by AHRI data showing a 2025 near-tie and early-2026 gains, amid persistent state/local incentives even after federal subsidies were rolled back.
Bright Saver launches zero-markup balcony solar DIY kits in the US starting around $300, with a membership-based discount model, while regulatory and pricing dynamics shape adoption and payback.
New York State enacted an executive order halting permits for new data centers 50 MW and larger, pending environmental review, with a potential one-year moratorium and additional legislative moves targeting 20 MW+ projects.
Subscribe for real-time drug updates and unlimited access to our intelligence platform.